Abstract 47P
Background
Studies have shown disparities in management of older patients with breast cancer, resulting in undertreatment. Older patients with co-morbidities pose a challenge for cancer care providers who must balance the risk of death due to toxicity from treatment versus the benefit of standard multimodality treatment. The aim of the study was to evaluate whether the sequencing of chemotherapy and surgery impact the ability to deliver both modalities of treatment.
Methods
A retrospective analysis of prospective data was evaluated between 2018 and 2022. We included patients >60 years of age with chronic comorbidities, with a clinical stage T1c-3 and N0-3, HER2-positive or triple-negative invasive breast cancer treated with chemotherapy alone, surgery alone, or both surgery and chemotherapy. Kaplan-Meier curves were plotted to compare the survival outcomes. Statistical analysis was done using SPSS v25.
Results
A total of 821 patients met the inclusion criteria, of whom 85.9% (N=705) underwent surgery as the initial treatment. Among patients who received chemotherapy first (N=116), 73.3% (N=85) were able to complete subsequent surgery. Factors associated with completion surgery after chemotherapy were younger age and clinical node-negative status. Among patients treated with surgery first, only 36.3% (N=256) received adjuvant chemotherapy. Among patients who received both modalities of treatment (N=341), women with more advanced stage tumors and those diagnosed in recent years were more likely to receive neoadjuvant chemotherapy. With a median follow-up of 19.3 months, cN0 patients who underwent both surgery and chemotherapy had significantly better overall survival compared to patients who received single modality of treatment.
Conclusions
In older, triple-negative or HER2-positive breast cancer patients with comorbidities, receipt of chemotherapy and surgery was associated with improved survival. Neoadjuvant chemotherapy group were twice as likely to receive both modalities of treatment than those undergoing surgery first. A multidisciplinary approach to evaluate geriatric patients with comorbidities is essential to deliver appropriate treatment and improve outcomes in this vulnerable population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract